Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9157319 | 0.98 | ALDH1A1 (0.38) | ALDH1A1LDHASRRNAMPTTSHR | |
| SCHEMBL157312 | 0.81 | — | — | |
| SCHEMBL14193699 | 0.81 | MGAM (0.39) | NAMPTTSHRHSD17B10 | |
| SCHEMBL27390467 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LDHASRRTSHRBLM | |
| SCHEMBL28344240 | 0.80 | PLA2G4B (0.38) | ALDH1A1LDHASRRTSHRPLA2G4B | |
| SCHEMBL102373 | 0.79 | ALDH1A1 (0.43) | ALDH1A1NAMPTTSHRBLMPMP22 | |
| SCHEMBL3791284 | 0.79 | ALDH1A1 (0.43) | ALDH1A1NAMPTTSHRBLMPMP22 | |
| SCHEMBL18244613 | 0.79 | ALDH1A1 (0.43) | ALDH1A1NAMPTTSHRBLMPMP22 | |
| SCHEMBL21876707 | 0.79 | ALDH1A1 (0.43) | ALDH1A1NAMPTTSHRBLMPMP22 | |
| SCHEMBL14660364 | 0.79 | ALDH1A1 (0.43) | ALDH1A1NAMPTTSHRBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075342-A1 | Pyrrolopyridazine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-07 | — | — | US | disclosed |
| EP-1115782-B1 | METHOD OF PREPARING A STERILE ARTICLE | OCCIDENTAL CHEM CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6113852-A | A POLY(VINYL CHLORIDE) OR POLYVINYLIDENE CHLORIDE POLYMER IS PRODUCED THAT CONTAINS ABOUT 0.001 TO ABOUT 5 WT % OF A ZINC COMPLEX | OCCIDENTAL CHEMICAL CORPORATION (US) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075342-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | ALDH1A1 328/4885LDHA 1671/4885SRR 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.